We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SOGROYA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
SOGROYA
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
somapacitan
Registration type
NCE/NBE
Indication
SOGROYA (solution for injection) is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).